There is precedence for associating HIF-1 expression with drug resistance in different cancer cell types, including chronic myeloid leukemia cells[66], gastric cancer cells[67], non-small cell lung cancer cells[68], and even breast cancer cells[58]. This evidence concerns the gene HIF1A and chronic myelogenous leukemia, BCR-ABL1 positive.